RxDoctor Payments Data

Marcus Loo, MD

Urology · New York, NYNPI 1053315614

Payments from drug & device makers

$2,969in general payments, 2019–2025

Across 131 payments — averaging $22.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Merck$384
  • AbbVie$361
  • Johnson & Johnson$297
  • Pfizer$192
  • Myovant Sciences Inc.$89
  • plus $505 from 16 others

What the payments were for

  • Food & beverage$2,69291%
  • Education$2779%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,969 in reported general payments places this provider in the 50th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$124,022
Medicare patients
284
Services billed
1,329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron415$327,279
Tamsulosin Hcl2,757$31,195
Finasteride2,675$25,726
GemtesaVibegron34$20,511
Silodosin138$15,382
Alfuzosin Hcl ErAlfuzosin Hcl273$6,654
Dutasteride234$6,507
Potassium Citrate ErPotassium Citrate62$3,299
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst214$2,300
Ciprofloxacin Hcl779$2,101
Oxybutynin Chloride ErOxybutynin Chloride117$1,836
Solifenacin Succinate26$1,117
Doxazosin Mesylate94$1,032
Cephalexin84$694
Bicalutamide17$589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,141$327,279415 claims
Sumitomo Pharma America, Inc.Gemtesa$65$20,51134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 952 urology providers in New York.

Other urology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →